Related Experiment Video
Updated: Aug 1, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder
M Steiner1, S J Romano, S Babcock
1McMaster University, St. Joseph's Hospital, Hamilton, Ontario, Canada.
Objective:
To determine the effectiveness of fluoxetine in alleviating physical symptoms of premenstrual dysphoric disorder.
Design:
Randomised, double-blind, placebo controlled, parallel study.
Setting:
Canadian University based outpatient clinics. Participants Four hundred and five subjects, of whom 320 with prospectively determined premenstrual dysphoric disorder were randomised.
Methods:
Randomised women were assigned to fluoxetine 20 or 60 mg/day or placebo. Common physical symptoms associated with premenstrual dysphoric disorder including breast tenderness, bloating, and headache were evaluated by visual analog scales and the self-rated and observer premenstrual tension syndrome scales.
Outcome Measures:
Luteal phase change from mean baseline scores to mean treatment scores for all scales.
Results:
Fluoxetine treatment was statistically superior to placebo, with no significant differences between the two fluoxetine dosages in their effects on physical symptoms.
Conclusion:
Daily fluoxetine treatment is superior to placebo in improving the most common physical symptoms associated with premenstrual dysphoric disorder.
More Related Videos
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
13:18Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
Published on: April 10, 2026
Related Concept Videos
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Disorders of the Female Reproductive System